Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosylate versus propofol for painless ERCP sedation
ChiCTR2400080926Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Third Hospital
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and propofol in choledocholithiasis (2 arms), sponsored by Shandong Provincial Third Hospital. Primary endpoints: Induction time, Hemodynamic indicators and 4 more. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
remimazolampropofol
03
Conditions
choledocholithiasis
Beyond the preview
Go deeper on ChiCTR2400080926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080926.